بررسی اثر داروی ضد سرطانی پومالیدومید بر فعالیت حیاتی و القای آپوپتوز سلول‌های تک هسته‌ای مغز استخوان

Background and Objective: Pomalidomide - a combination of Lenalidomide and Thalidomide drugs- is one of the newest anticancer drugs. Pomalidomide induces apoptosis in cancer cells. Furthermore, few studies indicating its relatively low cytotoxic effects on normal peripheral blood cells have been carried out. However, there is yet no information about the effects of Pomalidomide on bone marrow cells that contain important immune cells. In this study, the effect of Pomalidomide on normal bone marrow mononuclear cells was studied. Materials and Methods: The samples obtained from individuals who clinically needed bone marrow examination, but finally were diagnosed with no serious pathologic conditions in their leukocytes. Remained bone marrow aspirates were obtained and mononuclear cells were isolated. Half of the mononuclear cells were cultured with Pomalidomide (final concentration 10μM) and the remaining half (control group) were cultured with media alone. After 48h incubation, vital activity (MTT) and cell apoptosis induction rates were assessed. Results: The results showed that the vital activity of bone marrow mononuclear cells cultured in the presence of Pomalidomide increased significantly compared to the control group (P<0.05). However, Pomalidomide had no apoptosis induction and the rate of apoptotic cells had no significant difference with control group. Conclusion: Pomalidomide moderately stimulates the viability (or activity) of normal bone marrow mononuclear cells to improve and maintain them. Also, unlike most anticancer drugs it has no observable toxic effect or apoptosis induction on these cells. So, it may be concluded that Pomalidomide may be more favorable in preventing the side effects of anticancer drugs on normal cells. References 1- Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007 39(7): 1489-99. 2- Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 24(1): 22-32. 3- Shalapour S, Zelmer A, Pfau M, et al. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells invitro and invivo. Clin Cancer Res. 2006 12(18): 5526-32. 4- Baskić D, Popović S, Ristić P, Arsenijević NN. Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int. 2006 30(11): 924-32. 5- Lacy MQ. New immunomodulatory drugs in myeloma. Curr Hematol Malig Rep. 2011 6(2): 120-5. 6- Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. 2012 36(10): 1218-24. 7- Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 116(17): 3227-37. 8- Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs. 2011 20(5): 691-700. 9- Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 305(3): 1222-32. 10- Marriott J, Clarke I, Dredge K, Muller G, Stirling D, Dalgleish A. Thalidomide and its analogues have distinct and opposing effects on TNF- α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin & Exp Immunol. 2002 130(1): 75-84. 11- Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma. 2011 52(4): 560-6. 12- Ahmadbeigi N, Soleimani M, Mortazavi Y. The efficiency of density gradient for separation of mesenchymal stem cells from bone marrow sample. Zanjan Unv Med Sci J. 2011 19 (77): 62-69. 13- Hernández P, Cortina L, Artaza H, et al. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: A comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis. 2007 194(2): e52-e6. 14- Hay FC, Westwood OM. Practical immunology 4th edition. UK: Wiley 2008. 15- Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013 122(14): 2305-9. 16- Chanan-Khan A, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013 3(9): e143. 17- Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004 4(4): 314-22. 18- Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 122(1): 1-6. 19- Nicholas A, Boon MA, Nicki R, Brian R, Walker JA, Hunter D. Principle And practice of medicine. 20th Edition. UK: Churchill Livingstone 2006. 20- Liu W, Henry J, Meyer B, Bartlett J, Dalgleish A, Galustian C. Inhibition of metastatic potential in colorectal carcinoma invivo and invitro using immunomodulatory drugs (IMiDs). Br J Cancer. 2009 101(5): 803-12. 21- Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008 118(1): 248-58. 22- Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 27: 4563-9.